@prefix this: . @prefix sub: . @prefix beldoc: . @prefix rdfs: . @prefix rdf: . @prefix xsd: . @prefix dct: . @prefix dce: . @prefix pav: . @prefix np: . @prefix belv: . @prefix prov: . @prefix chebi: . @prefix schem: . @prefix species: . @prefix occursIn: . @prefix pubmed: . @prefix orcid: . sub:Head { this: np:hasAssertion sub:assertion; np:hasProvenance sub:provenance; np:hasPublicationInfo sub:pubinfo; a np:Nanopublication . } sub:assertion { sub:_1 occursIn: species:9606; rdf:object schem:Adenosine%20triphosphate; rdf:predicate belv:decreases; rdf:subject chebi:8147; a rdf:Statement . sub:assertion rdfs:label "a(CHEBI:phosphoenolpyruvate) -| a(SCHEM:\"Adenosine triphosphate\")" . } sub:provenance { beldoc: dce:description "Approximately 61,000 statements."; dce:rights "Copyright (c) 2011-2012, Selventa. All rights reserved."; dce:title "BEL Framework Large Corpus Document"; pav:authoredBy sub:_3; pav:version "20131211" . sub:_2 prov:value "Phosphoenolpyruvate (PEP) is a potent inhibitor of muscle creatine kinase. The inhibition of ATP formation is more pronounced at pH 7.0. The substrates, creatine and creatine phosphate, partially prevent the inhibition of the enzyme activity by PEP, creatine being as an effector."; prov:wasQuotedFrom pubmed:19862 . sub:_3 rdfs:label "Selventa" . sub:assertion prov:hadPrimarySource pubmed:19862; prov:wasDerivedFrom beldoc:, sub:_2 . } sub:pubinfo { this: dct:created "2014-07-03T14:33:37.460+02:00"^^xsd:dateTime; pav:createdBy orcid:0000-0001-6818-334X, orcid:0000-0002-1267-0234 . }